Amplifier Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amplifier Therapeutics - overview
Established
2023
Location
New York, NY, US
Primary Industry
Biotechnology
About
Based in New York, US, and founded in 2013, Amplifier TX AB d. b. a Amplifier Therapeutics is a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging, including metabolic conditions, cardiovascular diseases, kidney diseases, and cancer. In October 2023, Amplifier Therapeutics raised series A funding led by investor Cambrian Biopharma, with participation from other investors Future Ventures and RA Capital Management.
The company engages in the development of a compound called ATX-304, which activates AMPK. ATX-304 has the potential to treat various conditions, particularly those related to aging, such as heart and kidney diseases, diabetes, and cancer. It may also be a potential treatment for obesity.
Current Investors
RA Capital Management, Future Ventures, Cambrian Biopharma
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.amplifier-tx.com/
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.